ArticleJournal of clinical apheresis2026
Evaluation of Hemoadsorption Capacity of the CytoSorb Adsorber for Toxic Doses of Diclofenac and Meloxicam in Porcine Plasma.
Article in Journal of clinical apheresis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this in vitro experimental was to determine the utility of hemoadsorption (HA) using the CytoSorb adsorber to remove meloxicam and diclofenac from porcine plasma. For this purpose 12 1-L aliquots of porcine plasma, 6 units were spiked with 293 μg/mL (262-320 μg/mL) diclofenac and 6 with 42.8 μg/mL (41.4-44.7 μg/mL) meloxicam, respectively. Each unit was processed in a circular setup with the CytoSorb adsorber using the PuriFi HA platform until a recirculated volume of 20 L was reached. Pre- and post-adsorber samples were obtained at seven time points. Percentage reduction, clearance, and change from baseline were calculated. Drug concentrations were compared using Friedmann test with post hoc Dunn's multiple comparison test and Wilcoxon matched pairs rank sum test. p < 0.05 were considered significant. Diclofenac was reduced by a median of 242 mg (204-262 mg; 82.1%; 77.0%-83.6%). Total clearance was 40.5 mL/min (33.2-46.2 mL/min). Clearance at a plasma flow of 100 mL/min decreased from 39.9 mL/min (25.3-46.6 mL/min) at 0.2 L to 6.4 mL/min (-3.8 to 14.8 mL/min) at 20 L. Median reduction of meloxicam was 40.4 mg (38.6-42.2 mg; 94.4%; 93.2%-94.6%); total clearance was 94.38 mL/min (93.2-94.6 mL/min). Clearance at a plasma flow of 100 mL/min decreased from 65.3 mL/min (56.7-71.7 mL/min) at 0.2 L to 3.6 mL/min (-13.0 to 4.2 mL/min) at 20 L. HA using the CytoSorb adsorber successfully removed meloxicam and diclofenac from porcine plasma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.